Table 2.

Analysis of associations between interferon score and clinical parameters after 1000-times random sampling

	Complete group (n = 182)		Cross-validation
	p Value	BH-corrected p value	Significant results (p < 0.05)			Median p values
			Both sets	One set	Neither set	Set 1	Set 2
Disease parameters
Disease duration	0.061	0.25	0	371	629	0.18	0.20
DAS28	0.18	0.41	0	199	801	0.38	0.32
TJC28	0.10	0.36	0	264	736	0.25	0.25
SJC28	0.61	0.76	1	39	960	0.53	0.59
VAS	0.21	0.44	0	122	878	0.39	0.35
Erosions	0.41	0.60	0	61	939	0.50	0.51
Nodules	0.24	0.46	1	143	856	0.39	0.41
Laboratory parameters
ESR	0.86	0.98	6	18	976	0.60	0.58
ESR dichotomous (>20)	0.71	0.85	0	19	981	0.60	0.58
CRP	0.14	0.39	0	233	767	0.30	0.29
CRP dichotomous (≥10)	0.15	0.38	0	190	810	0.30	0.33
RF titer	0.36	0.60	1	66	933	0.46	0.50
RF positivity	0.96	1.0	3	3	994	0.62	0.61
ACPA titer	0.38	0.59	0	64	936	0.47	0.51
ACPA positivity	0.86	0.98	1	9	990	0.64	0.64
ACPA high positivity (≥3× cutoff)	0.29	0.52	0	79	921	0.44	0.44
RF- and ACPA-positive vs. rest	0.57	0.79	0	34	966	0.59	0.58
RF- and ACPA-negative vs. rest	0.13	0.41	0	219	781	0.27	0.28
Medication parameters
MTX use			2	3	995	0.66	0.65
MTX dosage	0.57	0.79	1	29	970	0.58	0.58
Prednisone use	0.037	0.19	0	526	474	0.14	0.14
Prednisone dosage	0.017	0.14	0	718	282	0.092	0.090
HCQ use	0.001	0.013	521	479	0	0.015	0.015
SSZ use	0.023	0.14	0	584	416	0.11	0.11
PREDN and/or HCQ and/or SSZ use	0.00032	0.0080	612	388	0	0.012	0.010

Abbreviations: BH Benjamini-Hochberg, HCQ Hydroxychloroquine, SSZ Sulfasalazine, PREDN Prednisone, ACPA Anti-citrullinated protein antibodies, CRP C-reactive protein, DAS28 28-joint Disease Activity Score, DMARD Disease-modifying antirheumatic drug, ESR Erythrocyte sedimentation rate, RF Rheumatoid factor, MTX Methotrexate, SJC28 Swollen joint count in 28 joints, TJC28 Tender joint count in 28 joints, VAS Visual analogue scale